9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
45 hedge funds and large institutions have $20.1M invested in 9 Meters Biopharma in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
183% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 6
101% more call options, than puts
Call options by funds: $859K | Put options by funds: $427K
25% more funds holding
Funds holding: 36 → 45 (+9)
57% less capital invested
Capital invested by funds: $46.7M → $20.1M (-$26.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.59M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.21M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.58M |
| 4 |
State Street
Boston,
Massachusetts
|
+$993K |
| 5 |
JG
Jefferies Group
New York
|
+$848K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$7.84M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$504K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$340K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$210K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$56.9K |
NMTR Hedge Fund Activity: Q3 2018 in Review
45 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q3 2018, worth a combined $20.1M — down 57% from $46.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NMTR positions and 3 closed out — a net gain of 9 holders — while 17 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $2.59M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $7.84M sold.
- 45 institutional investors held 9 Meters Biopharma (NMTR) as of Q3 2018, up from 36 in Q2 2018.
- Funds reported $20.1M of 9 Meters Biopharma stock for Q3 2018, down 57% quarter-over-quarter.
- 12 funds opened new 9 Meters Biopharma positions in Q3 2018 and 3 closed out, a net change of +9 holders.
- The largest 9 Meters Biopharma buyer in Q3 2018 was BlackRock, an estimated $2.59M added.
- The largest 9 Meters Biopharma seller in Q3 2018 was Sphera Funds Management, an estimated $7.84M sold.
Based on aggregated 13F filings for Q3 2018.